Mirae Asset Global ETFs Holdings’s Cytokinetics CYTK Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.61M	Buy	65,697 +4,520	+7%	+$325K	0.01%	823
2026 Q1	$4.02M	Buy	61,177 +1,542	+3%	+$98K	0.01%	881
2025 Q4	$3.78M	Buy	59,635 +143	+0.2%	+$8.9K	0.01%	897
2025 Q3	$3.26M	Sell	59,492 -12,818	-18%	-$528K	0.01%	944
2025 Q2	$2.39M	Sell	72,310 -2,608	-3%	-$90.7K	﹤0.01%	1016
2025 Q1	$3.03M	Buy	74,918 +3,260	+5%	+$150K	0.01%	927
2024 Q4	$3.37M	Buy	71,658 +659	+0.9%	+$34.2K	0.01%	888
2024 Q3	$3.74M	Buy	70,999 +7,340	+12%	+$409K	0.01%	862
2024 Q2	$3.45M	Buy	+63,659	New	+$3.84M	0.01%	875

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CYTK Position: Q2 2026 in Review

Mirae Asset Global ETFs Holdings increased its Cytokinetics (CYTK) stake by 7.4% in Q2 2026, buying an estimated $325K and bringing the position to 65,697 shares worth $5.61M. The position accounts for 0.01% of the portfolio, ranked #823.

Mirae Asset Global ETFs Holdings first reported a position in CYTK in Q2 2024 and has held it in 9 quarters since. 484 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Mirae Asset Global ETFs Holdings held 65,697 shares of Cytokinetics worth $5.61M as of Q2 2026.
Mirae Asset Global ETFs Holdings bought 4,520 Cytokinetics shares in Q2 2026, an estimated $325K.
Cytokinetics made up 0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q2 2026, its #823 holding.
Mirae Asset Global ETFs Holdings first reported a position in Cytokinetics in Q2 2024 and has held it in 9 quarters since.
484 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.